Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hodgkin Disease 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Neoplasms by Site 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7ofatumumab 4ibrutinib 4Rituximab 2KW-2478 2Dasatinib 2Alemtuzumab 2ziconotide 1sodium luminolate 1ruxolitinib 1oblimersen 1obinutuzumab 1mocetinostat 1milatuzumab 1ixekizumab 1fludarabine 1fenebrutinib 1baricitinib 1abexinostat 1Saline Solution 1Lenalidomide 1Hsp90 inhibitor KU757 1Etanercept 1Cyclophosphamide 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × abexinostat × Lymphoid × Clear all
NCT01149668 2013-06-19

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Pharmacyclics LLC.

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡